Net Present Value Model: Imfinzi
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Imfinzi Drug Details
Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed death-ligand 1 (PD-L1) blocking antibody. It is formulated as solution and concentrate solution for intravenous route of administration. Imfinzi is indicated as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC). and for the treatment of patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT), 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide), and adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine and cisplatin.It is under development for the treatment of advanced or metastatic papillary renal cell carcinoma, poorly differentiated thyroid carcinoma, anaplastic thyroid cancer, follicular thyroid cancer, medullary thyroid cancer and papillary thyroid cancer, HER2 negative metastatic breast cancer, esophageal squamous cell carcinoma, secondary central nervous system lymphoma and secondary diffuse large B-cell lymphoma (DLBCL), pulmonary sarcomatoid carcinoma, bile duct cancer, non-small cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, recurrent head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC), head and neck cancer squamous cell carcinoma, hepatocellular carcinoma, metastatic biliary tract cancer, esophageal cancer, Epstein-Barr virus positive (EBV+) nasopharyngeal carcinoma, adenocarcinoma of the gastro-esophageal junction, renal cell carcinoma, ovarian cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, muscle invasive bladder cancer (MIBC), mycosis fungoides, sezary syndrome, malignant pleural mesothelioma, myelodysplastic syndrome, small-cell lung cancer, non-muscle invasive bladder cancer (NMIBC) (superficial bladder cancer), endometrial cancer, diffuse large b-cell lymphoma, primary mediastinal B-cell lymphoma, follicular thyroid cancer, oropharyngeal cancer, human papillomavirus (HPV) associated cancer, t-cell lymphomas, primary mediastinal b-cell lymphoma, germ cell tumors, soft tissue sarcoma, transitional cell carcinoma (urothelial cell carcinoma), b-cell chronic lymphocytic leukemia, lymphoma, refractory multiple myeloma, relapsed multiple myeloma, B-cell non-Hodgkin lymphoma, breast cancer, triple-negative breast cancer, endometrial cancer, hormone-sensitive prostate cancer, esophageal cancer, primary CNS lymphoma, small-cell lung cancer, malignant pleural mesothelioma, fallopian tube cancer, peritoneal cancer, oropharyngeal cancer, metastatic breast cancer, ovarian cancer, metastatic adenocarcinoma of the pancreas, vulvar cancer, vaginal cancer, human papillomavirus (HPV) associated cancer, gastric cancer, pancreatic ductal adenocarcinoma, esophageal cancer, melanoma, oral cavity (mouth) cancer, leiomyosarcoma, gallbladder cancer, metastatic melanoma, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic biliary tract cancer, papillary renal cell carcinoma, metastatic renal cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), angiosarcoma, dedifferentiated liposarcoma, osteosarcoma, bladder carcinoma, ureter cancer, urethral cancer, chronic lymphocytic leukemia (CLL).It was also under development for metastatic cervical cancer, neuroendocrine tumor, multiple myeloma (Kahler disease) as firstline therapy, relapsed and refractory multiple myeloma, diffuse large B-cell lymphoma, peripheral T-cell lymphomas (PTCL), Post-Polycythemia Vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (POST-ET MF), primary myelofibrosis, B-cell chronic lymphocytic leukemia, lymphoma and recurrent head and neck cancer squamous cell carcinoma (first line therapy) and unspecified cancer.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.